749-P: Advancing Therapy in Uncontrolled Basal Insulin (BI)-Treated Type 2 Diabetes (T2D): Subanalysis of the SoliMix Trial Outside Europe

Introduction: In many regions outside Europe, premix insulin is commonly used to advance therapy from BI when HbA1c targets are not met in T2D, despite a greater risk of hypoglycemia and weight gain than with BI. Methods: SoliMix, an open-label, multicenter, randomized study, compared once-daily iGlarLixi to twice-daily premix insulin analog (BiAsp 70/30) in adults with T2D and HbA1c ≥7.5-≤10 % on BI + oral antihyperglycemic drugs (OADs). Co-primary endpoints were non-inferiority in HbA1c reduction or superiority in bodyweight change from baseline to Week 26 of iGlarLixi vs. BiAsp 70/30. This predefined subanalysis assesses SoliMix endpoints in participants outside Europe at the time of the study (57% of the total study population). Results: Both co-primary endpoints were met, as well as iGlarLixi superiority vs. BiAsp 70/30 in HbA1c reduction (Table). Significantly more iGlarLixi-treated participants reached HbA1c